Your browser doesn't support javascript.
Prolonged SARS-CoV-2 infection following rituximab treatment: clinical course and response to therapeutic interventions correlated with quantitative viral cultures and cycle threshold values.
Thornton, Christina S; Huntley, Kevin; Berenger, Byron M; Bristow, Michael; Evans, David H; Fonseca, Kevin; Franko, Angela; Gillrie, Mark R; Lin, Yi-Chan; Povitz, Marcus; Shafey, Mona; Conly, John M; Tremblay, Alain.
  • Thornton CS; Department of Medicine, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada.
  • Huntley K; Department of Medicine, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada.
  • Berenger BM; Alberta Precision Laboratories, Alberta Public Health Laboratory, Calgary, AB, Canada.
  • Bristow M; Department of Pathology and Laboratory Medicine, University of Calgary, Calgary, AB, Canada.
  • Evans DH; Department of Radiology, University of Calgary, Calgary, AB, Canada.
  • Fonseca K; Department of Cardiac Sciences, University of Calgary, Calgary, AB, Canada.
  • Franko A; Department of Medical Microbiology and Immunology and Li Ka Shing Institute of Virology, University of Alberta, Calgary, AB, Canada.
  • Gillrie MR; Alberta Precision Laboratories, Alberta Public Health Laboratory, Calgary, AB, Canada.
  • Lin YC; Department of Microbiology, Immunology and Infectious Diseases, University of Calgary, Calgary, AB, Canada.
  • Povitz M; Department of Pathology and Laboratory Medicine, University of Calgary, Calgary, AB, Canada.
  • Shafey M; Department of Medicine, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada.
  • Conly JM; Department of Microbiology, Immunology and Infectious Diseases, University of Calgary, Calgary, AB, Canada.
  • Tremblay A; Department of Medical Microbiology and Immunology and Li Ka Shing Institute of Virology, University of Alberta, Calgary, AB, Canada.
Antimicrob Resist Infect Control ; 11(1): 28, 2022 02 05.
Article in English | MEDLINE | ID: covidwho-1673926
ABSTRACT

BACKGROUND:

Detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) RNA is completed through reverse transcriptase-PCR (RT-PCR) from either oropharyngeal or nasopharyngeal swabs, critically important for diagnostics but also from an infection control lens. Recent studies have suggested that COVID-19 patients can demonstrate prolonged viral shedding with immunosuppression as a key risk factor. CASE PRESENTATION We present a case of an immunocompromised patient with SARS-CoV-2 infection demonstrating prolonged infectious viral shedding for 189 days with virus cultivability and clinical relapse with an identical strain based on whole genome sequencing, requiring a multi-modal therapeutic approach. We correlated clinical parameters, PCR cycle thresholds and viral culture until eventual resolution.

CONCLUSIONS:

We successfully demonstrate resolution of viral shedding, administration of COVID-19 vaccination and maintenance of viral clearance. This case highlights implications in the immunosuppressed patient towards infection prevention and control that should consider those with prolonged viral shedding and may require ancillary testing to fully elucidate viral activity. Furthermore, this case raises several stimulating questions around complex COVID-19 patients around the role of steroids, effect of antiviral therapies in absence of B-cells, role for vaccination and the requirement of a multi-modal approach to eventually have successful clearance of the virus.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Virus Shedding / Rituximab / SARS-CoV-2 / COVID-19 Type of study: Case report / Experimental Studies / Observational study / Prognostic study Topics: Vaccines Limits: Humans / Male / Middle aged Language: English Journal: Antimicrob Resist Infect Control Year: 2022 Document Type: Article Affiliation country: S13756-022-01067-1

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Virus Shedding / Rituximab / SARS-CoV-2 / COVID-19 Type of study: Case report / Experimental Studies / Observational study / Prognostic study Topics: Vaccines Limits: Humans / Male / Middle aged Language: English Journal: Antimicrob Resist Infect Control Year: 2022 Document Type: Article Affiliation country: S13756-022-01067-1